Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clini...
Q1 2026
May 12, 2026
FY 2025
Mar 24, 2026
Q4 2025
Q3 2025
Nov 13, 2025
Q2 2025
Aug 11, 2025
